Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) APC/Cy7 Anti-mouse/rat CD29 Antibody     Product Data Sheet (PDF)    
APC/Cy7 Anti-mouse/rat CD29 Antibody
1111125 25 µg $100.00       
1111130 100 µg $280.00       
Clone: HMβ1-1
Isotype: Armenian Hamster IgG
Reactivity: Mouse, Rat
Immunogen: Purified mouse VLA-4 (α4β1, CD49d/CD29)
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC/Cy7 under optimal conditions. The solution is free of unconjugated APC/Cy7 and unconjugated antibody.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:

FC - Quality tested

Recommended Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application References:

1. Noto K, et al. 1995. Int. Immunol. 7:835.
2. Ridger VC, et al. 2001. J. Immunol. 166:3484.
3. Jia W, et al. 2005. Blood 106:3854.PubMed
4. Economopoulou M, et al. 2005. Blood 106:3831.
5. Lawson BR, et al. 2007. J. Immunol. 178:5366.
6. Eisenmann KM, et al. 2007. J. Biol. Chem. doi:10.1074/jbc.M703243200.PubMed
7. Hayashi Y, et al. 2008. Am J Physiol Gastrointest Liver Physiol. 294:G778. PubMed
8. Kim DT, et al. 2008. Blood 111:2929.PubMed
9. Hayashi Y, et al. 2008. J Pharmacol Exp Ther. 326:523. PubMed
10. Carlson TR, et al. 2008. Development. 135:2193. PubMed
11. Sangaletti S, et al. 2008. Cancer Res. 68:9050. (Block) PubMed
12. Elsarrai HS, et al. 2013. J Cell Sci. 126:2446. PubMed

C57BL/6 bone marrow cells stained

C57BL/6 bone marrow cells stained with HMb1-1 APC/Cy7



Description:

CD29 is a 130 kD protein, also known as integrin β1, VLA-β chain, or GPIIa. It is a member of the integrin family, expressed broadly on leukocytes, endothelial cells, smooth muscle, and epithelial cells. In association with CD49a-f, CD29 forms the VLA-1 through VLA-6 complexes, respectively. It plays an important role in cell-cell or cell-matrix interaction. The HMß1-1 antibody reacts with both mouse and rat CD29. It is able to block cell adhesion and inhibit T cell proliferation.

Other Names: integrin β1, VLA-β chain, β1 integrin, GPIIa, ITGB1
Structure: Integrin family, 130 kD
Distribution: Leukocytes, endothelial cells, smooth muscle, epithelial cells
Function: Adhesion
Ligand Receptor: Extracellular matrix
Antigen References:

1. Noto K, et al. 1995. Int. Immunol. 7:835.
2. Springer TA. 1990. Nature 346:425.


This product or portions thereof is manufactured under license from GE Healthcare under U.S. Patent Numbers 5,268,486; 5,569,587; 5,627,027 and patents or pending applications that are continuations, continuations-in-part, re-examinations, divisionals, reissues or foreign equivalents thereof. THIS MATERIAL IS SUBJECT TO PROPRIETARY RIGHTS OF GE HEALTHCARE BIO-SCIENCES CORP. AND CARNEGIE MELLON UNIVERSITY AND MADE AND SOLD UNDER LICENSE FROM GE HEALTHCARE BIO-SCIENCES CORP. THIS PRODUCT IS LICENSED FOR SALE ONLY FOR RESEARCH. IT IS NOT LICENSED FOR ANY OTHER USE. THERE IS NO IMPLIED LICENSE HEREUNDER FOR ANY COMMERCIAL USE.
COMMERCIAL USE shall include:

  • sale, lease, license or other transfer of the material or any material derived or produced from it;
  • sale, lease, license or other grant of rights to use this Material or any material derived or produced from it;
  • use of this material to perform services for a fee for third parties.

IF YOU REQUIRE A COMMERCIAL LICENSE TO USE THIS MATERIAL AND DO NOT HAVE ONE RETURN THIS MATERIAL, UNOPENED TO Sony Biotechnology Inc., 2100 South Oak Street, Champaign, IL 61820, USA AND ANY MONEY PAID FOR THE MATERIAL WILL BE REFUNDED.